Table 6B. The Associations between TSPYL6 polymorphisms and clinical characteristics of breast cancer patients.

Variables	rs11896604					rs843706
	GG + CG	CC	ORa	95% CI	Pb	CA + CC	AA	ORa	95% CI	Pb
Age	55	128				144	39
≤ 40	16	41	1	(reference)		41	16	1	(reference)
> 40	39	87	1.149	(0.576–2.291)	0.694	103	23	1.748	(0.839–3.639)	0.133
Age of Menarche	55	128				144	39
≤ 12	6	19	1	(reference)		22	3	1	(reference)
> 12	49	109	0.702	(0.264–1.868)	0.477	122	36	2.164	(0.612–7.646)	0.221
BMI	55	128				144	39
≤ 24	38	83	1	(reference)		98	23	1	(reference)
> 24	17	45	0.825	(0.419–1.624)	0.578	46	16	0.675	90.326–1.397	0.288
Breastfeeding Duration	51	119				133	37
≤ 6	3	9	1	(reference)		10	2	1	(reference)
> 6	48	110	0.764	(0.198–2.946)	0.695	123	35	1.423	(0.298–6.797)	0.657
Clinical Stages	55	128				144	39
I/II	43	92	1	(reference)		112	23	1	(reference)
III/IV	12	36	0.713	(0.338–1.505)	0.374	32	16	0.411	(0.194–0.869)	0.018**
Estrogen Receptor	55	128				144	39
negative	19	41	1	(reference)		49	11	1	(reference)
positive	36	87	0.893	(0.458–1.742)	0.74	95	28	0.762	(0.350–1.658)	0.492
Family Tumor History	55	128				144	39
no	45	111	1	(reference)		121	35	1	(reference)
yes	10	17	1.151	(0.617–3.410)	0.391	23	4	1.663	(0.539–5.131)	0.372
Procreative Times	52	123				138	37
< 1	41	101	1	(reference)		112	30	1	(reference)
≥ 1	11	22	0.812	(0.361–1.824)	0.614	26	7	1.005	(0.398–2.539)	0.991
Progestrone Receptor	55	128				144	39
negative	25	50	1	(reference)		59	16	1	(reference)
positive	30	78	0.769	(0.406–1.457)	0.42	85	23	1.002	(0.488–2.058)	0.995
Tumor Location	55	128				144	39
left	25	59	1	(reference)		66	18	1	(reference)
right	30	67	1	(reference)		77	20	1	(reference)
both	0	2	---	---	0.638	1	1	---	---	0.603
Tumor Size (cm)	55	128				144	39
≤ 3	27	67	1	(reference)		76	18	1	(reference)
> 3	28	61	1.139	(0.605–2.144)	0.686	68	21	0.767	(0.377–1.559)	0.463
Tumor Type	55	128				144	39
Infiltrating ductal carcinoma	52	113	1	(reference)		128	37
others	3	15	2.301	(0.638–8.295)	0.192	16	2	0.432	(0.095–1.967)	0.266
Incipience/Recurrence	54	128				144	38
Incipience	24	85	1	(reference)		92	17	1	(reference)
Recurrence	30	43	2.471	(1.290–4.734)	0.006*	52	21	0.458	(0.222–0.944)	0.032*
Lymph node metastasis	54	126				141	39
no	33	72	1	(reference)		83	22	1	(reference)
yes	21	54	0.848	(0.442–1.627)	0.621	58	17	0.904	(0.442–1.851)	0.783
Menopause	55	128				144	39
no	32	83	1	(reference)		87	28	1	(reference)
yes	23	45	1.326	(0.694–2.532)	0.393	57	11	1.668	(0.770–3.614)	0.192
Primiparous Age	52	124				139	37
< 30	50	120	1	(reference)		136	34	1	(reference)
≥ 30	2	4	0.833	(0.148–4.697)	0.836	3	3	4	(0.773–20.70)	0.076

BMI: body mass index; CI: confidence interval. OR: odds ratio.

^aAdjusted for Age, Age of Menarche, BMI, Breastfeeding Duration, Clinical Stages, Estrogen Receptor, Family Tumor History, Procreative Times, Progestrone Receptor, Tumor Location, Tumor Size (cm), Tumor Type, Incipient/Recurrence, Lymph node metastasis, Menopause and Primiparous Age.

^bTwo-sided Chi-square test for the distributions of genotype frequencies.

^*p < 0.05 indicates statistical significance.